Recent Finacing
Recent Raise
Selexys Pharmaceuticals develops antibody therapeutics targeting P‑selectin and PSGL‑1 for inflammation, thrombosis, and metastasis, advancing SelG1 in Phase 2 for sickle cell and anti‑PSGL‑1 into Phase I.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor